Docebo Certified as Diamond Level Smartchoice® Preferred Provider by Brandon Hall Group
Boca Raton, FL, March 27, 2025 (GLOBE NEWSWIRE) -- After an extensive review, Brandon Hall Group confirms that Docebo is living its mission to power true learning transformation that drives lasting business success for organizations worldwide.
Michael Rochelle, Chief Strategy Officer and Principal HCM Analyst at Brandon Hall Group, showed continued trust in Docebo, saying, 'Docebo exemplifies what it means to be a pioneering force in learning technology. Their ability to not only anticipate but also shape the future of learning development and talent management is evident in the impact they drive across industries. This certification is a testament to their innovation, setting the benchmark for excellence in learning and development. Their vision goes beyond technology: it's about empowering organizations to build agile, high-performing teams and create meaningful change in the way people learn, work, and grow.'
The analyst team at Brandon Hall Group has invested a considerable amount of time and energy understanding Docebo's differentiated solution and the rapidly evolving customer requirements in the markets they serve. The team has conducted in depth briefings and a thorough evaluation of Docebo's product/service value proposition.
Brandon Hall Group's Smartchoice® Preferred Provider Program provides a world-class membership center for knowledge, resources, and advisory support to the entire Docebo organization to ensure our Diamond certification is a reflection of the highest standards a Provider can attain in the market.
"Being recognized as a Diamond Level Smartchoice® Preferred Provider is a testament to the transformation we're driving in learning technology," said Alessio Artuffo, CEO of Docebo. 'Docebo is no longer just an LMS—we are building the enterprise learning platform of the future. At Docebo, we're proud to lead the shift toward an AI platform that unifies content creation, delivery, and personalization in one modern and cohesive ecosystem. This recognition affirms our belief that real innovation comes not from hype but from solving real problems at scale—for learners, businesses, and the future of work.
Brandon Hall Group has consistently been the leading independent analyst firm and confirms that Docebo offerings measurably benefit the organizations they work with.
To learn more about Smartchoice® preferred vendors or to become one, please visit https://brandonhall.com/solutions-providers-offerings/preferred-providers/
To learn more about Docebo, visit www.Docebo.com.
---About Brandon Hall Group Inc.
Brandon Hall Group is the only professional development company that offers data, research, insights and certification to Learning and Talent executives and organizations. The best minds in Human Capital Management (HCM) choose Brandon Hall Group to help them create future proof employee development plans for the new era.
For over 30 years, we have empowered, recognized and certified excellence in organizations around the world influencing the development of over 10,000,000 employees and executives. Our HCM Excellence Awards was the first to recognize organizations for learning and talent and is the gold standard, known as the 'Academy Awards of Human Capital Management.'
Our cloud-based platform delivers evidence-based insights in the areas of Learning and Development, Talent Management, Leadership Development, Diversity and Inclusion, Talent Acquisition and HR/Workforce Management for corporate organizations and HCM solution Providers.
To learn more visit https://www.brandonhall.com
---About Docebo
Docebo (NASDAQ:DCBO; TSX:DCBO) is redefining the way enterprises leverage technology to create and manage content, deliver training, and measure the business impact of their learning programs. With Docebo's end-to-end AI learning platform, organizations worldwide are equipped to deliver scaled, personalized learning across all their audiences and use cases, driving growth and powering their business.
Learn why businesses around the world trust Docebo by visiting our customer stories page.
CONTACT: David Forry Brandon Hall Group 5613538082 David.forry@brandonhall.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Femasys Announces FemSperm™ Kit to Activate Gynecologists and Advance FemaSeed® Fertility Platform
-- First in the FemSperm family, the Setup Kit enables gynecologists to offer FemaSeed directly, expanding access ahead of IVF and driving revenue growth -- ATLANTA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, today announced the introduction of its FemSperm Setup Kit, the first in a planned family of products designed to fully enable gynecologists for FemaSeed Intratubal Insemination. The setup kit includes customized components, such as a pre-configured centrifuge to optimize sperm preparation for use with FemaSeed. By providing a streamlined, in-office solution, Femasys is establishing the foundation for gynecologist-driven adoption of FemaSeed as a first-step fertility treatment, expanding patient access to alternatives ahead of IVF and advancing the Company's commercialization strategy. 'Our FemSperm Setup Kit represents the beginning of a broader family of products designed to fully activate gynecologists to adopt and expand FemaSeed use,' said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc. 'This strategic step strengthens our commercialization pathway by bringing FemaSeed into the hands of the physicians who see patients first, opening new access points for women seeking fertility care and positioning Femasys for scalable revenue growth.' "With decades of experience in reproductive medicine and as an investigator in the completed FemaSeed trial, I performed the procedure firsthand and know it is ideally suited for gynecologists to perform," said Dr. James Liu, Chief Medical Officer of Femasys and Former Chairman, Department of Obstetrics and Gynecology, University Hospital System, Former Chair, Department of Reproductive Biology, Case Western Reserve University and Former Division Director of Reproductive Endocrinology and Infertility, University of Cincinnati. "Introducing sperm preparation into the gynecology office is a necessary step to enable this pathway. With FemaSeed, fertility care can begin in the gynecologist's practice, the primary setting for family planning, making treatment more accessible and affordable for women earlier in their fertility journey." FemaSeed is a next-generation artificial insemination solution that enhances natural fertilization by precisely delivering sperm to the fallopian tube, the site of conception. Positioned as a true first step in the fertility journey, FemaSeed offers safe, accessible, and cost-effective alternative to intrauterine insemination (IUI). In its pivotal trial, FemaSeed established more than double the pregnancy rates compared to IUI in cases of low male sperm count.1 As an affordable, less invasive, lower-risk option before IVF, FemaSeed is authorized for use in the U.S., Europe, UK, Canada, Israel, Australia and New Zealand. Learn more at About FemasysFemasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys' fertility portfolio includes FemaSeed® Intratubal Insemination, a groundbreaking first-step infertility treatment and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrates FemaSeed is over twice as effective as traditional IUI, with a comparable safety profile, and high patient and practitioner satisfaction.1 FemBloc® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June of 2025 followed by UK in August 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going. Learn more at or follow us on X, Facebook and LinkedIn. References1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08. 2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05. Forward-Looking Statements This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'pending,' 'intend,' 'believe,' 'suggests,' 'potential,' 'hope,' or 'continue' or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law. Contacts: Investors: IR@ Media Contact: Media@
Yahoo
an hour ago
- Yahoo
Medical Device Testing Market Size Attains USD 24.32 Bn by 2034
The global medical device testing market is valued at USD 10.77 billion in 2025 and is projected to grow to approximately USD 24.32 billion by 2034, expanding at a CAGR of 9.47% during the forecast period. Ottawa, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The global medical device testing market size was valued at USD 9.84 billion in 2024 and is projected to reach approximately USD 24.32 billion by 2034, expanding at a CAGR of 9.47% over the forecast period, according to a study published by Towards Healthcare, a sister firm of Precedence Research. A rise in the need for trustworthy and high-quality medical devices is propelling the expansion of the global market. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways Asia-Pacific led the global medical device testing market in 2024. North America is expected to witness rapid expansion during 2025-2034. By service, the biocompatibility tests segment was dominant in the market in 2024. By service, the chemistry tests segment is expected to register significant growth in the coming years. By phase, the clinical segment held the dominating share of the global medical device testing market in 2024. By phase, the preclinical segment is expected to grow at a notable CAGR during 2025-2034. Market Overview & Potential A process in which the evaluation of the safety, efficiency, and performance of medical devices is conducted, termed medical device testing. Across the globe, the global medical device testing market is experiencing growing regulatory strictness, technological breakthroughs, and a rising healthcare sector. In 2025, it comprises major developments in in-vitro diagnostics (IVD), and the execution of the EU's Medical Device Regulation (MDR) around the market. Usually, it encompasses the evaluation, functionality, durability, sterility, biocompatibility, electrical safety, and usability of the medical device. What are the Key Growth Drivers Involved in The Expansion of The Market? In 2025, several growth factors are impacting the overall development of the global medical device testing market. The growing geriatric population associated with chronic concerns is driving demand for diverse medical devices involved in diabetes management, mobility assistance, and remote patient monitoring. Along with this, an emerging strict regulatory landscape, such as the FDA and the EU's MDR, is offering strong testing guidelines for safety and efficacy. Majorly, different developing medical device producers, particularly startups, are highly outsourcing testing to specialized firms, resulting in market growth. Become a valued research partner with us - What are the Key Drifts Involved in the Market? In August 2025, BDC Laboratories, a leading player in cardiovascular device testing solutions, entered into a strategic partnership with the newly established Dilawri Cardiovascular Institute (DCI) to enhance focus on the development and clinical validation of cardiovascular medical devices. In October 2024, NAMSA, a leader in MedTech Contract Research Organization (CRO) offering end-to-end market access services, and TERUMO, a global player in medical technology, partnered to expand the regulatory approval and commercialization of Terumo's product portfolio. What is the Emerging Challenge in the Market? The need for significant investment in specialized equipment, skilled personnel, and ongoing compliance efforts is creating a major hindrance in the global medical device testing market. Alongside, the widespread requirement for specialized knowledge and skills in areas like biocompatibility, sterilization, and electrical safety is evolving into a barrier to the development of the market. Regional Analysis Why Did Asia Pacific Dominate the Market in 2024? Across the global medical device testing market, the Asia Pacific was dominant in 2024. China, India, and Japan are experiencing a vital expansion due to increasing economies and growing disposable incomes. This ultimately results in a rise in investment in the healthcare system and medical devices, propelling the adoption of various testing services. Additionally, faster advances in different technologies, such as miniaturization, digitalization, and the development of new materials, are enhancing the need for specialized testing March 2025, UL Solutions Inc., a major player in applied safety science, announced its expansion of Songshan Lake IoT Laboratory in Dongguan, China, to support manufacturers in navigating the complexities of connected product and wireless device testing and market access. What Made North America Significantly Grow in the Market in 2024? During 2025-2034, North America is predicted to expand at a rapid CAGR in the global medical device testing market. Merging high R&D investment by many medical device companies, like the adoption of technologies like AI and automation, in this region, is fueling overall market development. Also, North America is focusing on patient safety and regulatory compliance, especially in the US, which requires rigorous testing throughout the product January 2025, Argon Medical Devices enrolled the first patient in a US-based study exploring a newer catheter-based device for managing blood clots in the lungs. In June 2025, Ash, a leading at-home health testing platform, and Impilo, a leader in offering at-home healthcare, partnered to deliver feasible at-home health monitoring and testing nationwide. You can place an order or ask any questions, please feel free to contact us at sales@ Segmental Insights By service analysis Which Service Led the Medical Device Testing Market in 2024? The biocompatibility tests segment held the largest revenue share of the market in 2024. Around the globe, numerous medical device manufacturers are preferring biocompatibility testing to achieve market acceptance and develop a robust reputation for quality and safety. Along with this, these tests are important for reducing the risk of adverse reactions, infections, and other difficulties linked with medical devices. This leads to ensuring patient safety and improving device efficacy. Whereas the chemistry tests segment is predicted to grow rapidly during 2025-2034. Several advantages of this segment are the assessment of the possible toxicity of medical devices and confirming that they will not react negatively with the body. Additionally, the chemistry tests are widely employed in broader devices, from simple disposables to complex implants, to ensure their safety and regulatory compliance. Primarily, they comprise the identification of chemical compounds of a medical device and examination of probable risks linked with their presence, which further assist in biocompatibility assessment. By phase analysis How did the Clinical Segment Hold a Major Share of the Market in 2024? The clinical segment dominated the global medical device testing market in 2024. Usually, different phases of clinical trials offer significant real-world evidence that assists healthcare professionals in making informed decisions about device usage and expands the continuous optimization of medical devices. A surge in 3D printing and AI in medical device manufacturing is boosting the need for clinical trials to study the performance and safety of these new technologies. Also, the segment is driven by the accelerating need for advanced medical devices, a focus on patient safety and efficacy, and a rise in regulatory scrutiny. The preclinical segment is predicted to witness significant expansion in the studied years. Ongoing developments in biocompatibility testing, microbiology testing, and package validation are widely impacting the development of the preclinical phase of the market. Furthermore, various medical device industries, especially small-scale ones, have a shortage of resources or well-trained personnel to execute complete preclinical testing in-house. This further propels the demand for specialized preclinical testing service providers. Whereas, currently growing diverse chronic diseases are fueling demand for enhanced patient safety, which ultimately relies on the development of the preclinical phase. Get the latest insights on healthcare industry segmentation with our Annual Membership: Recent Developments In July 2025, Siemens Healthineers launched the CN-3000 and CN-6000 Hemostasis Systems for coagulation testing in Canada. In May 2025, Roche unveiled the Elecsys PRO-C3 test for the evaluation of the liver fibrosis severity in individuals with signs of metabolic dysfunction–associated steatotic liver disease (MASLD). In March 2025, Nelson Labs launched a groundbreaking rapid sterility testing to notably expedite product sterility results. In October 2024, UPM Biomedicals, the forerunner in producing high quality nanofibrillar cellulose for medical and life science applications, introduced FibGel, a natural injectable hydrogel for permanent implantable medical devices. Medical Device Testing Market Key Players SGS SA Laboratory Corporation of America Holdings Nelson Laboratories, LLC TÜV SÜD Charles River Laboratories Element Minnetonka North America Science Associates Inc. (NAMSA) Eurofins Scientific Pace Analytical Services LLC Intertek Group Plc WuXi AppTec Browse More Insights of Towards Healthcare: The global medical device contract manufacturing market is valued at USD 78.61 billion in 2024, expected to grow to USD 87.14 billion in 2025, and projected to reach approximately USD 220.57 billion by 2034, expanding at a CAGR of 10.86% between 2025 and 2034. The global medical device outsourcing market is estimated at USD 160.3 billion in 2024, rising to USD 180.59 billion in 2025, and forecasted to hit nearly USD 507.89 billion by 2034, advancing at a CAGR of 12.65% during 2025–2034. The global pain management devices market stands at USD 7.68 billion in 2024, increasing to USD 8.41 billion in 2025, and is anticipated to reach around USD 19.1 billion by 2034, growing at a CAGR of 9.54% over the forecast period. The global medical device CRO market is valued at USD 8.49 billion in 2024, set to rise to USD 9.25 billion in 2025, and projected to surpass USD 19.9 billion by 2034, at a CAGR of 8.98% between 2025 and 2034. The global wearable medical devices market is calculated at USD 42.78 billion in 2024, climbing to USD 53.68 billion in 2025, and expected to surge to nearly USD 408.61 billion by 2034, registering a strong CAGR of 25.57% from 2025 to 2034. The global implantable medical devices market is estimated at USD 97.17 billion in 2024, growing to USD 103.14 billion in 2025, and forecasted to reach around USD 176.33 billion by 2034, advancing at a CAGR of 6.14% during 2025–2034. The medical device gaskets & seals market was valued at USD 0.92 billion in 2023 and is projected to expand to USD 1.57 billion by 2034, progressing at a CAGR of 5% from 2024 to 2034. The 3D-printed medical devices market is expected to grow from USD 5.59 billion in 2025 to approximately USD 24.69 billion by 2034, witnessing a robust CAGR of 17.94% over the forecast period. The global endoscopy devices market size is valued at USD 61.1 billion in 2024, projected to increase to USD 63.44 billion in 2025, and estimated to reach USD 88.55 billion by 2034, registering a CAGR of 3.82% between 2025 and 2034. The global rehabilitation equipment market is valued at USD 17 billion in 2024, expected to rise to USD 18.42 billion in 2025, and projected to hit USD 37.34 billion by 2034, expanding at a CAGR of 8.34% from 2025 to 2034. Segments Covered in The Report By Service Biocompatibility Tests Cardiovascular Device's Biocompatibility Tests Orthopedic Device's Biocompatibility Tests Dental Implant Devices' Biocompatibility Tests Dermal Filler's Biocompatibility Tests General Surgery Implantation Devices Biocompatibility Tests Neurosurgical Implantation Devices Biocompatibility Tests Ophthalmic Implantation Device's Biocompatibility Tests Others Chemistry Test Chemical characterization (E&L) Analytical method development and validation Toxicological Risk Assessment and consulting Microbiology & Sterility Test Bioburden Determination Pyrogen & Endotoxin Testing Sterility Test & Validation Antimicrobial Testing Others Package Validation By Phase Preclinical Large animal research Biocompatibility Tests Chemistry Test Microbiology & Sterility Test Small animal research Biocompatibility Tests Chemistry Test Microbiology & Sterility Test Clinical By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: Immediate Delivery Available | Buy This Premium Research @ About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region: +44 778 256 0738 North America Region: +1 8044 4193 44 APAC Region: +91 9356 9282 04 Web: Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | PinterestError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Avetta Empowers Customers to Strengthen Supply Chain Resilience Amid Economic Uncertainty with Enhanced Risk Intelligence
LEHI, Utah & HOUSTON--(BUSINESS WIRE)-- Avetta ®, the leading provider of supply chain risk management (SCRM) software, today announced major advancements to the Business Risk solution and Sanctions and Adverse Media solution within its AI-powered Avetta One platform. The enhancements help clients respond more effectively to today's economic volatility by providing clearer, more actionable insights into supplier and contractor risk. Organizations are under increasing pressure to reduce costs, maintain efficient supply chains and modernize procurement operations all while navigating inflation, labor shortages and geopolitical disruptions. In fact, recent data from The Hackett Group shows that procurement leaders rank improving spend reduction, ensuring supply chain continuity and combating inflationary price increases among their top priorities. The refined solutions announced today directly address these challenges and priorities by improving visibility into supplier and contractor vulnerabilities—such as financial instability, regulatory compliance gaps and reputational risks—and enabling faster, more confident decision-making. 'Economic uncertainty is no longer a temporary condition—it's the new normal,' said Dawn Andre, Chief Product Officer at Avetta. 'Our enhanced Business Risk solution and Sanctions and Adverse Media solution give clients the clear and accurate intelligence they need to act decisively amid shifting market conditions and operational complexity. By surfacing meaningful insights and eliminating blind spots through innovative design and powerful data, we continue to help our customers gain the clarity, speed and confidence to not just respond to disruption, but anticipate it and turn it into opportunity.' Business Risk Avetta's Business Risk solution provides clients with a comprehensive view of supplier and contractor financial health, operational stability and compliance posture. It aggregates and analyzes data across these key risk indicators and provides risk scores for individual suppliers and contractors. By uniquely allowing procurement, legal and compliance teams to integrate their workflows, it dramatically improves efficiency—enabling teams to enforce compliance policies from directly within the platform—and eliminates hidden risks. With the latest developments, the solution now reveals critical scoring trends to illustrate the direction a specific score is moving, along with contextual explanations that clarify what a score means and how it compares to industry benchmarks. This helps clients better interpret changes and make faster, more informed decisions without needing to consult external documentation or analysis. Sanctions and Adverse Media The Sanctions and Adverse Media solution helps clients identify potential regulatory and reputational risks among their suppliers and contractors. It scans global databases, government lists and news sources to detect potential issues. Going beyond exact name matches, the solution now surfaces multiple relevant reports—including near matches, related entities and location-based data—giving clients a more comprehensive view of potential risks. This expanded visibility helps ensure that critical issues are not overlooked, and that clients can triage risks more effectively and prioritize follow-up actions with greater confidence. To learn more, visit About Avetta The Avetta SaaS platform helps clients manage supply chain risk and their suppliers become more qualified for jobs. For hiring clients, we offer the world's largest supply chain risk management network to manage supplier safety, sustainability, worker competency and performance. We perform contractor prequalification and worker competency management across major industries all over the globe, including construction, energy, facilities, high tech, manufacturing, mining and telecom.
